Double Bond Pharmaceutical (DBP) and Helixor Heilmittel GmbH have today signed an agreement for distribution of Helixor products in Sweden. The distribution will be held through Drugsson AB.
Helixor products are used as integrative cancer therapy, which means that they are given to the patient to decrease severe side effects from their current medication and substantially increase quality of life. Helixor products are available for integrative treatment of different types of cancers, both common and rare cancers, including breast cancer, colorectal cancer, lung cancer and brain cancer.
“In line with our goal to build a self-sustaining pharmaceutical company with a balanced portfolio consisting of both innovative developmental products and ready-to-sell unique products we are very pleased to be able to add a first oncology product to Drugsson’s portfolio – says Igor Lokot, CEO of Double Bond Pharma – Quality of life becomes a more and more important parameter in cancer treatment and we are proud to be a distributor of Helixor as part of integrative cancer therapy”.
Helixor products are already registered on the EU market and I Sweden, and are expected to generate first revenues to Drugsson in Q4 2018.
More about Helixor
This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 29 of May 2018.
Full Company Name:
Double Bond Pharmaceutical International AB (publ)
Stock short name:
Share ISIN code:
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.